Trial · NCT07880405
Multimodal Imaging Analysis in Post-Stroke Thalamic Pain: A Retrospective Study
NCT07880405, Completed, Aerospace Center Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Multimodal Imaging Analysis in Post-Stroke Thalamic Pain: A Retrospective Study. Trials, record NCT07880405. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07880405
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Multimodal Imaging Analysis in Post-Stroke Thalamic Pain: A Retrospective Study
- NCT number
- NCT07880405
- Status
- Completed
- Enrollment
- 50 participants, actual
- Lead sponsor
- Aerospace Center Hospital
- Conditions
- Central Post-stroke Pain, Thalamic Pain Syndrome, Stroke
- First posted
- 2026-10-19
- Last updated
- 2026-10-19
Source ClinicalTrials.gov
Registered outcomes24
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Pain severity assessed by Visual Analog Scale (VAS) | Baseline (preoperative), 1 month postoperative, 6 months postoperative, and 12 months postoperative. | VAS scores extracted from medical records. Scores range from 0 (no pain) to 10 (worst possible pain), with higher scores indicating greater pain severity. |
| Secondary | Pain severity assessed by Short-Form McGill Pain Questionnaire (SF-MPQ) | Baseline (preoperative), 1 month postoperative, 6 months postoperative, and 12 months postoperative. | The SF-MPQ is a validated self-report measure of pain quality and intensity. It includes a 15-item Pain Rating Index (PRI; 11 sensory and 4 affective descriptors, each scored 0-3; total PRI range 0-45), a Present Pain Intensity (PPI) index (0-5), and a VAS (0-10). Higher PRI, PPI, and VAS scores indicate greater pain severity. Sensory scores reflect pain quality, while affective scores reflect pain-related emotional distress. Scores were extracted from medical records. |
| Secondary | Pain catastrophizing assessed by Pain Catastrophizing Scale (PCS) | Baseline (preoperative), 1 month postoperative, 6 months postoperative, and 12 months postoperative. | The PCS is a 13-item self-report scale measuring catastrophic thoughts and feelings about pain. Each item is scored 0-4, giving a total score range of 0-52. It includes three subscales: rumination, magnification, and helplessness. Higher total scores indicate greater pain catastrophizing; a total score ≥30 is commonly used to indicate clinically relevant catastrophizing. Scores were extracted from medical records. |
| Secondary | Fractional anisotropy (FA) of corticothalamic pathways | Baseline (preoperative). | FA values measured from DTI. Higher FA indicates greater white matter integrity. |
| Secondary | Thalamic gray matter volume | Baseline (preoperative). | Gray matter volume of the thalamus measured from high-resolution T1-weighted MRI. |
| Secondary | Resting-state functional connectivity within the default mode network (DMN) | Baseline (preoperative). | Resting-state functional connectivity within the DMN was calculated from rs-fMRI data as the correlation of spontaneous BOLD signal fluctuations among key DMN regions (e.g., medial prefrontal cortex, posterior cingulate cortex/precuneus, and lateral parietal cortex). Values are typically Fisher z-transformed correlation coefficients; higher values indicate stronger within-network functional connectivity. Data were extracted retrospectively from imaging archives. |
| Secondary | Resting-state functional connectivity within the salience network (SN) | Baseline (preoperative). | Resting-state functional connectivity within the SN was calculated from rs-fMRI data as the correlation of spontaneous BOLD signal fluctuations among key SN regions (e.g., anterior insula and dorsal anterior cingulate cortex). Values are typically Fisher z-transformed correlation coefficients; higher values indicate stronger within-network functional connectivity. Data were extracted retrospectively from imaging archives. |
| Secondary | Resting-state functional connectivity within the sensorimotor network (SMN) | Baseline (preoperative). | Resting-state functional connectivity within the SMN was calculated from rs-fMRI data as the correlation of spontaneous BOLD signal fluctuations among key SMN regions (e.g., primary sensorimotor cortex, supplementary motor area, and premotor cortex). Values are typically Fisher z-transformed correlation coefficients; higher values indicate stronger within-network functional connectivity. Data were extracted retrospectively from imaging archives. |
| Secondary | Glutamate/GABA ratio in the thalamus | Baseline (preoperative). | Glutamate/GABA ratio measured by MRS in the thalamus.Glutamate is the main excitatory neurotransmitter and GABA the main inhibitory neurotransmitter; the ratio reflects the balance between excitation and inhibition in this region. Higher values indicate relatively increased excitatory or decreased inhibitory tone. The ratio is unitless. Data were extracted retrospectively from imaging archives. |
| Secondary | Glutamate/GABA ratio in the anterior cingulate cortex (ACC) | Baseline (preoperative). | Glutamate/GABA ratio measured by MRS in the ACC.Glutamate is the main excitatory neurotransmitter and GABA the main inhibitory neurotransmitter; the ratio reflects the balance between excitation and inhibition in this region. Higher values indicate relatively increased excitatory or decreased inhibitory tone. The ratio is unitless. Data were extracted retrospectively from imaging archives. |
1 to 10 of 24Source ClinicalTrials.gov
See all 24 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07880405
GET https://conductscience.org/api/trials/v1/NCT07880405/registered?page=2